Story

Rank Group Shares Surge After Upgrading Full-Year Profit Forecast

ENTHMSVIIDZHZH-TWJAKOHI
Jul 14, 20261 min read
Rank Group Shares Surge After Upgrading Full-Year Profit Forecast

Summary

Rank Group raised its full-year operating profit guidance to at least £76 million, citing strong digital growth and improved casino performance, sending its shares higher.

Text size
Background

Shares of Rank Group PLC surged after the company announced it expects full-year underlying operating profit to beat market expectations, driven by strong digital revenue and an improving performance at its Grosvenor casino locations.

Upgraded Financial Guidance

In a full-year trading update, the gaming operator said it now anticipates underlying operating profit will be at least £76 million. This upbeat forecast was supported by a 6% increase in group like-for-like net gaming revenue, which reached approximately £834.1 million for the full year.

The company attributed the strong results to sustained momentum in its digital division and a recovery across its physical casino estate. Rank Group also reaffirmed its medium-term goal of achieving at least £100 million in operating profit, signaling confidence in its longer-term business strategy.

Sample IUX Markets – In-articleAd

Market Reaction and Context

Investors reacted positively to the news, with Rank Group's stock climbing as much as 3.5% in morning trading. The advance stood in contrast to a more subdued broader market, where the mid-cap FTSE 250 index, of which Rank is a member, faced headwinds.

The update followed a constructive note from Shore Capital Group, which had reiterated its "house stock" rating on the company a day earlier. According to the source material, the consensus analyst price target for Rank Group sits significantly above its current trading level, suggesting that analysts see the shares as undervalued relative to their earnings potential.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST